What is DRUG's relative strength rating?

DRUG ranks at the 67th percentile over 1 month, 33th percentile over 3 months, 33th percentile over 6 months, 88th percentile over 1 year against the full TickerStance CS+ADRC universe of U.S. equities.

What sector is DRUG in?

DRUG is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data. Healthcare is currently ranked 3 of 11 sectors by relative strength.

Is DRUG in a leading sector?

Yes — Healthcare ranks at the 82th percentile by sector relative strength, placing it in the leading band (≥ 70th percentile). DRUG benefits from positive sector-level momentum, which historically correlates with above-average stock-level RS performance in the O'Neil / Minervini framework.

How volatile is DRUG?

DRUG currently shows a 20-day average daily range (ADR%) of 5.1%, a 90-day beta versus the S&P 500 of 1.50. An ADR% above 4% indicates an intraday swing-trading eligible name in the Minervini Volatility Contraction Pattern framework. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.

Does DRUG have a seasonal pattern?

TickerStance computes DRUG's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what DRUG has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.

When did DRUG last report earnings?

No SEC EDGAR filings are linked to DRUG in the current TickerStance fundamentals database. This can occur for tickers without a matched CIK (some ADRs, ETFs, and recently listed securities) or when the fundamentals pipeline has not yet processed this ticker.

Bright Minds Biosciences Inc. Common Stock (DRUG)

TODAY'S READ · AS OF 2026-08-24

As of 2026-08-24, Bright Minds Biosciences Inc. Common Stock (DRUG) has a 3-month relative strength percentile of 33 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 55. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 5.1%, relative volume 0.61×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.

RS methodology →

Market-wide RS; lit = leaderboard

Lenses lit

3 month33pctile

6 month33pctile

1 year88pctile

Classic66IBD pctile

LDR47leadership

0 of 5 lenses lit · avg RS pctile 53

✓ADR%5.1%!A/DC!RVOL0.61×✓$ Vol$18M

Market backdrop

47.8Neutral

Trend30% weight44.9 Breadth30% weight50.6 Leadership20% weight42.4 Macro20% weight59.0 Full stance breakdown →

§ Seasonality

10y · since 2022

Best monthOct on averageavg +963.78% · 25% win · n 4

Worst monthMar on averageavg -18.26% · 0% win · n 4

DRUG monthly seasonality strip
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
1	DRUG Jan avg: 10.57% median: -1.58% win: 25% σ: 27.07% n: 4 2022-04-12 → 2026-07-31	DRUG Feb avg: -4.80% median: -4.43% win: 50% σ: 15.63% n: 4 2022-04-12 → 2026-07-31	DRUG Mar avg: -18.26% median: -18.29% win: 0% σ: 13.08% n: 4 2022-04-12 → 2026-07-31	DRUG Apr avg: -0.76% median: -14.89% win: 40% σ: 31.35% n: 5 2022-04-12 → 2026-07-31	DRUG May avg: 5.49% median: 0.14% win: 60% σ: 16.16% n: 5 2022-04-12 → 2026-07-31	DRUG Jun avg: -13.29% median: -10.36% win: 20% σ: 10.78% n: 5 2022-04-12 → 2026-07-31	DRUG Jul avg: 22.20% median: 24.43% win: 100% σ: 17.11% n: 5 2022-04-12 → 2026-07-31	DRUG Aug avg: 12.79% median: 3.26% win: 50% σ: 59.51% n: 4 2022-04-12 → 2026-07-31 (current)	DRUG Sep avg: 1.21% median: -7.60% win: 50% σ: 41.57% n: 4 2022-04-12 → 2026-07-31	DRUG Oct avg: 963.78% median: -12.68% win: 25% σ: 1957.48% n: 4 2022-04-12 → 2026-07-31	DRUG Nov avg: 7.81% median: 4.68% win: 50% σ: 14.95% n: 4 2022-04-12 → 2026-07-31	DRUG Dec avg: -8.01% median: -5.71% win: 50% σ: 20.66% n: 4 2022-04-12 → 2026-07-31

Evidence · 1 of 3

Receipts behind the read

1 of 5 pass

Leadership

Is it leading?

Relative strength across horizons plus the leadership score.

1m

67

3m

33

6m

33

1y

88

LDR

—

StageWeinstein stage analysis

Stage 1 · Basing

Smart money

Who's accumulating?

Accumulation rating, relative volume, U/D ratio, breakout-day proof.

Fundamentals · DRUG

Does the business back the chart?

No SEC filings on file for this ticker. Fundamentals section requires EDGAR coverage.

Evidence · 2 of 3

Sector context

Healthcare · 82th pctile in sector

Top peers · Healthcare

Who else is leading?

ELOX
99RS 3m
FBRX
99RS 3m
MRNA
99RS 3m
DRUG
33RS 3m · you

Sector vs market

Healthcare · 3 of 11

Energy100

Technology91

Healthcare82

Financials

PEERS · Pharmaceutical Products

Same industry, closest relative strength

4 peers · by RS6M

SUPNSupernus Pharmaceuticals, Inc.33 STOKStoke Therapeutics, Inc. Common Stock33 EPRXEupraxia Pharmaceuticals Inc. Common Stock33 BDTXBlack Diamond Therapeutics, Inc. Common Stock33

ETF OWNERS

ETFs holding DRUG

DRUG is held by 11 ETFs as of May 2026. Top owner: VTWO at 0.02% weight, $3M notional. Top 3 carry $6M.

Held by 20 ETFs · $26M across latest filings · largest weight 4.55% (PSIL).

ETFs holding: 11
Total value: $7M
Top 3 concentration: 94.3%
Max weight: VFMO · 0.14%

Top 10 by value, from SEC N-PORT-P filings dated May 2026.

ETFs holding DRUG ranked by value
ETF	Weight	Value	Δ
VTWO	0.02%	$3M	—
VFMO	0.14%	$3M	—
VTWG	0.03%	$573K	—
GSSC	0.02%	$241K	new
VTHRVanguard Russell 3000 ETF	0.00%	$52K	—
ITWO

Public attention · DRUG

Is the crowd watching?

49/ 100 · vs its own 90-day norm▼ 11 vs 7dOverlooked

Weak relative strength and quiet attention. Little to read here either way.

Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.

News

Reference

Company snapshot

SectorHealthcare

IndustryPharmaceutical Products

SIC2834

Float6.6Mshares

Shares out9.8Mshares

Market cap$755.8MSmall Cap

FAQ

Frequently asked questions

What is DRUG's relative strength rating?: DRUG ranks at the 67th percentile over 1 month, 33th percentile over 3 months, 33th percentile over 6 months, 88th percentile over 1 year against the full TickerStance CS+ADRC universe of U.S. equities.
What sector is DRUG in?: DRUG is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data. Healthcare is currently ranked 3 of 11 sectors by relative strength.
Is DRUG in a leading sector?: Yes — Healthcare ranks at the 82th percentile by sector relative strength, placing it in the leading band (≥ 70th percentile). DRUG benefits from positive sector-level momentum, which historically correlates with above-average stock-level RS performance in the O'Neil / Minervini framework.
How volatile is DRUG?: DRUG currently shows a 20-day average daily range (ADR%) of 5.1%, a 90-day beta versus the S&P 500 of 1.50. An ADR% above 4% indicates an intraday swing-trading eligible name in the Minervini Volatility Contraction Pattern framework. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.
Does DRUG have a seasonal pattern?: TickerStance computes DRUG's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what DRUG has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.

Bright Minds Biosciences Inc. Common Stock (DRUG) — Stance & relative strength

Lenses lit

Market backdrop

§ Seasonality

Receipts behind the read

Is it leading?

Who's accumulating?

Does the business back the chart?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

ETFs holding DRUG

Is the crowd watching?

Company snapshot

Frequently asked questions

How much does it move?

§ Seasonality

Bright Minds Biosciences Inc. Common Stock (DRUG) — Stance & relative strength

DRUG is not confirmed as a leader. 33 is not yet a leadership-grade RS read, Market Stance is 47.8

Lenses lit

Market backdrop

Receipts behind the read

Is it leading?

Who's accumulating?

Does the business back the chart?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

ETFs holding DRUG

Is the crowd watching?

Company snapshot

Frequently asked questions

How much does it move?